ROSSARI BIOTECH Latest Share Price (ROSSARI)
TODAY IN ONE LINE
ROSSARI is little changed at ₹407.60 on light volume — a quiet consolidation day.
With a market cap of ₹2,255.09 Cr., it trades at a P/E of 14.76. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ROSSARI BIOTECH flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 33.5% YoY
- ●Reasonable ValuationTrading at a moderate P/E of 19.6x
- ●High Promoter HoldingPromoters hold 63.6% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.10x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest ROSSARI BIOTECH News
What changed recently?
Recent events, corporate actions, and announcements.
ROSSARI BIOTECH valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ROSSARI BIOTECH, framed against the sector median so the premium or discount is obvious at a glance.
ROSSARI BIOTECH trades at a P/E of 14.76× and P/B of 1.60×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ROSSARI BIOTECH technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ROSSARI BIOTECH — derived from the latest tape, not yesterday's close.
ROSSARI BIOTECH last traded at ₹407.6 with an intraday range of ₹405–₹414 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹407.60| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 430.73 | +23.13 | +5.68% |
| R3 | 421.73 | +14.13 | +3.47% |
| R2 | 417.87 | +10.27 | +2.52% |
| R1 | 412.73 | +5.13 | +1.26% |
| PIVOT | 408.87 | 1.27 | 0.31% |
| CURRENT | 407.60 | — | — |
| S1 | 403.73 | -3.87 | -0.95% |
| S2 | 399.87 | -7.73 | -1.90% |
| S3 | 394.73 | -12.87 | -3.16% |
| S4 | 385.73 | -21.87 | -5.36% |
ROSSARI is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹405.1–₹414
Trading Inside opening range
ROSSARI BIOTECH financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ROSSARI BIOTECH — consolidated or standalone — with margins, YoY growth and key ratios inline.
ROSSARI BIOTECH reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,255.09 Cr. and reported EPS of ₹7.02.
| Metric | Mar 2026 | Apr 2026 |
|---|---|---|
| Revenue from Operations | 2,396 | 2,396 ▲ 0.0% |
| Sales Growth YoY %Derived | 15.19% | 15.19% |
| Other Income | 22 | 22 ▲ 0.0% |
| Total Income | 2,419 | 2,419 ▲ 0.0% |
| 1,669 | 1,669 ▲ 0.0% | |
| Gross ProfitDerived | 728 | 728 ▲ 0.0% |
| Gross Margin %Derived | 30.36% | 30.36% |
| 442 | 442 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 286 | 286 ▲ 0.0% |
| OPM %Derived | 11.93% | 11.93% |
| 108 | 108 ▲ 0.0% | |
| Profit Before Tax (PBT) | 201 | 201 ▲ 0.0% |
| 53 | 53 ▲ 0.0% | |
| Effective Tax %Derived | 26.57% | 26.57% |
| Total Profit for Period | 149 | 149 ▲ 0.0% |
| Less: Non-controlling Interests | — | — |
| Net Profit (Owner's PAT)Derived | 149 | 149 ▲ 0.0% |
| Net Profit Margin %Derived | 6.23% | 6.23% |
| PAT Growth YoY %Derived | 9.41% | 9.41% |
| Earnings Per Share (EPS ₹) | 26.94 | 26.94 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% |
| Share of Profit from Associates/JVs | 2 | 2 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 2,218 | 2,218 ▲ 0.0% |
| Material Cost % of RevenueDerived | 66.92% | 66.92% |
| Employee Cost % of RevenueDerived | 6.46% | 6.46% |
| Other Cost % of RevenueDerived | 11.98% | 11.98% |
| Interest Coverage (x)Derived | 7.24x | 7.24x |
| Period | Mar 2021 | May 2021 | Mar 2022 | May 2022 | Mar 2023 | Apr 2023 | Mar 2024 | Apr 2024 | Mar 2025 | Apr 2025 | Mar 2026 | Apr 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 709 | 709 ▲ 0.0% | 1,483 ▲ 109.1% | 1,483 ▲ 0.0% | 1,656 ▲ 11.7% | 1,656 ▲ 0.0% | 1,831 ▲ 10.5% | 1,831 ▲ 0.0% | 2,080 ▲ 13.6% | 2,080 ▲ 0.0% | 2,396 ▲ 15.2% | 2,396 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 109.06% | 109.06% | 11.66% | — | 10.55% | 10.55% | 13.64% | 13.64% | 15.19% | 15.19% | |
| Other Income | 9 | 9 ▲ 0.0% | 12 ▲ 30.5% | 12 ▲ 0.0% | 5 ▼ 54.3% | 5 ▲ 0.0% | 7 ▲ 35.8% | 7 ▲ 0.0% | 4 ▼ 46.2% | 4 ▲ 0.0% | 22 ▲ 458.2% | 22 ▲ 0.0% | |
| Total Income | 719 | 719 ▲ 0.0% | 1,495 ▲ 108.1% | 1,495 ▲ 0.0% | 1,661 ▲ 11.1% | 1,661 ▲ 0.0% | 1,838 ▲ 10.6% | 1,838 ▲ 0.0% | 2,084 ▲ 13.4% | 2,084 ▲ 0.0% | 2,419 ▲ 16.0% | 2,419 ▲ 0.0% | |
462 | 462 ▲ 0.0% | 1,105 ▲ 139.1% | 1,105 ▲ 0.0% | 1,171 ▲ 6.0% | 1,171 ▲ 0.0% | 1,294 ▲ 10.4% | 1,294 ▲ 0.0% | 1,433 ▲ 10.8% | 1,433 ▲ 0.0% | 1,669 ▲ 16.4% | 1,669 ▲ 0.0% | ||
| Gross ProfitDerived | 247 | 247 ▲ 0.0% | 378 ▲ 52.9% | 378 ▲ 0.0% | 485 ▲ 28.2% | 485 ▲ 0.0% | 537 ▲ 10.8% | 537 ▲ 0.0% | 647 ▲ 20.5% | 647 ▲ 0.0% | 728 ▲ 12.5% | 728 ▲ 0.0% | |
| Gross Margin %Derived | 34.84% | 34.84% | 25.48% | 25.48% | 29.26% | 29.26% | 29.34% | 29.34% | 31.10% | 31.10% | 30.36% | 30.36% | |
124 | 124 ▲ 0.0% | 194 ▲ 56.7% | 194 ▲ 0.0% | 262 ▲ 34.5% | 262 ▲ 0.0% | 287 ▲ 9.8% | 287 ▲ 0.0% | 382 ▲ 32.9% | 382 ▲ 0.0% | 442 ▲ 15.7% | 442 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 123 | 123 ▲ 0.0% | 183 ▲ 49.1% | 183 ▲ 0.0% | 223 ▲ 21.6% | 223 ▲ 0.0% | 250 ▲ 12.0% | 250 ▲ 0.0% | 265 ▲ 6.1% | 265 ▲ 0.0% | 286 ▲ 7.9% | 286 ▲ 0.0% | |
| OPM %Derived | 17.35% | 17.35% | 12.37% | 12.37% | 13.47% | 13.47% | 13.64% | 13.64% | 12.74% | 12.74% | 11.93% | 11.93% | |
26 | 26 ▲ 0.0% | 61 ▲ 135.1% | 61 ▲ 0.0% | 85 ▲ 40.4% | 85 ▲ 0.0% | 80 ▼ 6.4% | 80 ▲ 0.0% | 85 ▲ 6.4% | 85 ▲ 0.0% | 108 ▲ 26.8% | 108 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 106 | 106 ▲ 0.0% | 135 ▲ 26.6% | 135 ▲ 0.0% | 143 ▲ 6.3% | 143 ▲ 0.0% | 177 ▲ 23.9% | 177 ▲ 0.0% | 184 ▲ 3.8% | 184 ▲ 0.0% | 201 ▲ 8.9% | 201 ▲ 0.0% | |
27 | 27 ▲ 0.0% | 39 ▲ 44.0% | 39 ▲ 0.0% | 37 ▼ 4.2% | 37 ▲ 0.0% | 47 ▲ 27.0% | 47 ▲ 0.0% | 49 ▲ 4.0% | 49 ▲ 0.0% | 53 ▲ 9.2% | 53 ▲ 0.0% | ||
| Effective Tax %Derived | 25.17% | 25.17% | 28.64% | 28.64% | 25.80% | 25.80% | 26.45% | 26.45% | 26.50% | 26.50% | 26.57% | 26.57% | |
| Total Profit for Period | 80 | 80 ▲ 0.0% | 98 ▲ 22.0% | 98 ▲ 0.0% | 107 ▲ 9.8% | 107 ▲ 0.0% | 131 ▲ 21.8% | 131 ▲ 0.0% | 136 ▲ 4.4% | 136 ▲ 0.0% | 149 ▲ 9.4% | 149 ▲ 0.0% | |
| Less: Non-controlling Interests | -0 | -0 ▲ 0.0% | 0 ▲ 112.1% | 0 ▲ 0.0% | — ▼ 100.0% | — | — | — | — | — | — | — | |
| Net Profit (Owner's PAT)Derived | 80 | 80 ▲ 0.0% | 98 ▲ 21.8% | 98 ▲ 0.0% | 107 ▲ 9.8% | 107 ▲ 0.0% | 131 ▲ 21.8% | 131 ▲ 0.0% | 136 ▲ 4.4% | 136 ▲ 0.0% | 149 ▲ 9.4% | 149 ▲ 0.0% | |
| Net Profit Margin %Derived | 11.31% | 11.31% | 6.59% | 6.59% | 6.48% | 6.48% | 7.14% | 7.14% | 6.56% | 6.56% | 6.23% | 6.23% | |
| PAT Growth YoY %Derived | — | — | 21.76% | 21.76% | 9.81% | — | 21.85% | 21.85% | 4.35% | 4.35% | 9.41% | 9.41% | |
| Earnings Per Share (EPS ₹) | 15.45 | 15.45 ▲ 0.0% | 17.74 ▲ 14.8% | 17.74 ▲ 0.0% | 19.45 ▲ 9.6% | 19.45 ▲ 0.0% | 23.66 ▲ 21.6% | 23.66 ▲ 0.0% | 24.63 ▲ 4.1% | 24.63 ▲ 0.0% | 26.94 ▲ 9.4% | 26.94 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 5 | 5 ▲ 0.0% | 6 ▲ 6.0% | 6 ▲ 0.0% | 6 ▲ 0.2% | 6 ▲ 0.0% | 6 ▲ 0.2% | 6 ▲ 0.0% | 6 ▲ 0.2% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 0 | 0 ▲ 0.0% | 2 ▲ 276.4% | 2 ▲ 0.0% | 1 ▼ 38.1% | 1 ▲ 0.0% | 0 ▼ 81.7% | 0 ▲ 0.0% | 1 ▲ 458.9% | 1 ▲ 0.0% | 2 ▲ 94.4% | 2 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% | 0 ▼ 19.8% | 0 ▲ 0.0% | 0 ▲ 252.9% | 0 ▲ 0.0% | 0 ▼ 97.0% | 0 ▲ 0.0% | -1 ▼ 11488.9% | -1 ▲ 0.0% | 0 ▲ 107.4% | 0 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 612 | 612 ▲ 0.0% | 1,360 ▲ 122.2% | 1,360 ▲ 0.0% | 1,518 ▲ 11.6% | 1,518 ▲ 0.0% | 1,661 ▲ 9.4% | 1,661 ▲ 0.0% | 1,900 ▲ 14.4% | 1,900 ▲ 0.0% | 2,218 ▲ 16.7% | 2,218 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 61.30% | 61.30% | 65.42% | 65.42% | 65.17% | 65.17% | 67.19% | 67.19% | 62.47% | 62.47% | 66.92% | 66.92% | |
| Employee Cost % of RevenueDerived | 5.92% | 5.92% | 4.58% | 4.58% | 5.96% | 5.96% | 5.63% | 5.63% | 6.36% | 6.36% | 6.46% | 6.46% | |
| Other Cost % of RevenueDerived | 11.58% | 11.58% | 8.53% | 8.53% | 9.84% | 9.84% | 10.06% | 10.06% | 12.00% | 12.00% | 11.98% | 11.98% | |
| Interest Coverage (x)Derived | 33.50x | 33.50x | 10.70x | 10.70x | 7.17x | 7.17x | 9.78x | 9.78x | 11.12x | 11.12x | 7.24x | 7.24x |
ROSSARI BIOTECH segment analysis : revenue and profit mix.
Disclosed business segments at ROSSARI BIOTECH with their share of revenue and profit, switchable between consolidated and standalone reporting.
ROSSARI BIOTECH discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ROSSARI BIOTECH.
Our AI distills the core fundamental drivers supporting ROSSARI BIOTECH, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 19 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.06%.
ROSSARI BIOTECH peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ROSSARI BIOTECH is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ROSSARI BIOTECH chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ROSSARI BIOTECH — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ROSSARI BIOTECH delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ROSSARI BIOTECH over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ROSSARI BIOTECH stood at 49.0% of traded volume, against a 20-day average of 52.2%.
ROSSARI BIOTECH announcements: results, concalls, ratings, M&A.
Filings ROSSARI BIOTECH sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ROSSARI BIOTECH files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 142 documents below.
Analysts/Institutional Investor Meet/Con. Call Updates
Intimation of Transcript of Q2 H1 FY 27 for the Earnings Conference Call held on October 19, 2026.
Analysts/Institutional Investor Meet/Con. Call Updates
Audio recording of Earnings Conference Call for Q2 & H1 FY 27.
Press Release
Rossari Biotech Limited informed the Exchange regarding Press Release for Q2 FY 27 Results
Investor Presentation
Rossari Biotech Limited has informed the Exchange about Investor Presentation
Copy of Newspaper Publication
Newspaper publication of extract of Consolidated Unaudited Financial Results for the quarter and half year ended September 30, 2026.
Investor decks & rating reports.
ROSSARI BIOTECH dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ROSSARI BIOTECH has declared, sequenced by announce and record date.
ROSSARI BIOTECH corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ROSSARI BIOTECH: business, sector, key facts.
What ROSSARI BIOTECH does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ROSSARI BIOTECH operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: ROSSARI, BSE: 543213.
Rossari Biotech Limited is a prominent Indian manufacturer and seller of specialty chemicals, serving both domestic and international markets. Their diverse portfolio encompasses a wide range of applications, showcasing their extensive capabilities within the chemical industry. This breadth allows them to cater to various sectors, demonstrating adaptability and a strategic focus on multiple revenue streams. The company's operational structure is built on a foundation of manufacturing and direct sales, giving them direct control over the production process and market access.
A significant portion of Rossari's business is dedicated to the production and distribution of chemicals for the soap and detergent industry. This is a substantial market segment, and Rossari's presence indicates their competitiveness and ability to meet the demands of this sector. Beyond detergents, they supply chemicals for inks, paints, coatings, ceramics, tiles, pulp and paper production, and cement manufacturing, highlighting the versatility of their chemical offerings and their significant contribution to several essential industrial processes.
Rossari further distinguishes itself through its specialized textile chemical offerings. This segment showcases a deep understanding of the textile industry's diverse needs. They provide chemicals tailored for various fabric types including cotton, polyester, acrylic, wool, silk, and nylon, demonstrating expertise in diverse textile processing techniques. Their commitment extends to functional finishes, denim processing, printing, and environmentally sustainable solutions, reflecting a focus on innovation and meeting contemporary industry demands.
In addition to its industrial chemical production, Rossari has expanded into consumer goods with its line of pet grooming products. These products, marketed under the brands Lozalo, Hunger Fills, and Sniffy, include shampoos, powders, deodorants, sprays, creams, and floor washing liquids. This diversification demonstrates a strategy to broaden their market reach and tap into consumer demand for pet care products. The company also produces poultry nutrition products, including vitamin-mineral formulations, enzyme blends, and herbal supplements, indicating expansion into the agricultural sector and the growing market for animal nutrition.
Founded in 1997 and headquartered in Mumbai, Rossari Biotech has evolved significantly since its inception as Rossari Labtech. The company's continuous growth and diversification illustrate a commitment to innovation, market expansion, and a strong understanding of various industry needs. Their success hinges on their ability to adapt to market trends and deliver high-quality chemical solutions for various sectors, ranging from industrial manufacturing to consumer products.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AARTI INDUSTRIES (AARTIIND) Share PricePeer
- AARTISURF (AARTISURF) Share PricePeer
- ARCHEAN CHEMICAL IND (ACI) Share PricePeer
- AETHER INDUSTRIES (AETHER) Share PricePeer
- ALKALI (ALKALI) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ROSSARI BIOTECH (ROSSARI).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ROSSARI BIOTECH (ROSSARI)?
The current share price of ROSSARI BIOTECH (ROSSARI) is ₹407.60. Today, the stock has declined by ₹0.80 (0.2%), trading in a range of ₹405.00 to ₹414.00. The stock opened at ₹414.00 with a trading volume of 49,434 shares.
02Is ROSSARI BIOTECH stock a good investment for long-term?
ROSSARI BIOTECH can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,255.09 Cr., P/E ratio of 14.76, ROE of 11.72%, and ROCE of 11.79%. The dividend yield stands at 0.12%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ROSSARI BIOTECH stock?
The 52-week high price of ROSSARI BIOTECH (ROSSARI) is ₹656.05, while the 52-week low is ₹375.00. Currently trading at ₹407.60, the stock is 8.69% above its 52-week low and 37.87% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ROSSARI BIOTECH stock at the current price?
Whether to buy ROSSARI BIOTECH stock at ₹407.60 depends on multiple factors. The stock is currently trading with a P/E ratio of 14.76 and P/B ratio of 1.6. Today's performance shows a loss of 0.2%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ROSSARI BIOTECH and when is the next dividend?
ROSSARI BIOTECH offers a dividend yield of 0.12%, which means for every ₹100 invested at the current price of ₹407.60, you can expect to receive approximately ₹0.12 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ROSSARI BIOTECH?
ROSSARI BIOTECH's key financial metrics include: P/E Ratio: 14.76, P/B Ratio: 1.6, ROE: 11.72%, ROCE: 11.79%, Dividend Yield: 0.12%, EPS: ₹7.02, Book Value: ₹240.70, and Debt-to-Equity: 0.1. The company's market cap stands at ₹2,255.09 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ROSSARI BIOTECH stock performing today in the market?
ROSSARI BIOTECH stock opened at ₹414.00 and is currently trading at ₹407.60, showing a decline of ₹0.80 (0.2%). The intraday high is ₹414.00 and low is ₹405.00. The trading volume stands at 49,434 shares, indicating moderate market participation today.
08What is the P/E ratio of ROSSARI BIOTECH and what does it indicate?
ROSSARI BIOTECH has a Price-to-Earnings (P/E) ratio of 14.76, which means investors are willing to pay 14.76 for every ₹1 of earnings. With an EPS of ₹7.02, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ROSSARI BIOTECH (ROSSARI) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.